Checkpoint Therapeutics, Inc.
CKPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -60.2% | -46.4% | -28.4% | – |
| Cost of Goods Sold | $0 | $44 | $50 | $48 |
| Gross Profit | $0 | -$43 | -$50 | -$48 |
| % Margin | 100% | -42,197.1% | -25,850.5% | -17,979.5% |
| R&D Expenses | $36 | $44 | $50 | $48 |
| G&A Expenses | $20 | $9 | $8 | $9 |
| SG&A Expenses | $20 | $9 | $9 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $56 | $52 | $59 | $57 |
| Operating Income | -$56 | -$52 | -$58 | -$57 |
| % Margin | -137,009.8% | -50,629.1% | -30,381.8% | -21,165.3% |
| Other Income/Exp. Net | -$0 | $0 | -$4 | $0 |
| Pre-Tax Income | -$56 | -$52 | -$63 | -$57 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$56 | -$52 | -$63 | -$57 |
| % Margin | -137,170.7% | -50,336.9% | -32,616.7% | -21,125.7% |
| EPS | -1.42 | -2.77 | -7.09 | -7.45 |
| % Growth | 48.7% | 60.9% | 4.8% | – |
| EPS Diluted | -1.42 | -2.77 | -7.09 | -7.45 |
| Weighted Avg Shares Out | 40 | 19 | 9 | 8 |
| Weighted Avg Shares Out Dil | 40 | 19 | 9 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $4 | $0 |
| EBITDA | -$56 | -$52 | -$54 | -$56 |
| % Margin | -137,009.8% | -50,629.1% | -28,063.5% | -21,077% |